Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
Trial details
- Registry ID
- NCT07795164
- Drugs studied
- Pemvidutide
TrialRedline tracks 7 clinical trials sponsored by Altimmune, Inc.: 1 Phase 3, 6 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHNCT07795164 | Pemvidutide | Recruiting | 2028-12Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860 | Pemvidutide | Active not recruiting | 2027-09-30Estimated |
| RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513 | Pemvidutide | Completed | 2026-07-30Actual |
| IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05989711 | Pemvidutide | Completed | 2025-11-25Actual |
| Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 | ALT-801 | Completed | 2023-09-28Actual |
| Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAXNCT03232567 | NasoVAX | Completed | 2018-03-07Actual |
| HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)NCT04684914 | HepTcell | Terminated | 2024-03-27Actual |
Names as written in the registry records.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Relative (%) change in liver stiffness by VCTE compared to baseline at Week 24. After: Measure: Relative (%) reduction in liver stiffness by VCTE compared to baseline.
Before: Estimated. After: Actual.
Before: 100 participants (planned). After: 121 participants (actual).
Before: 31 Mar 2027. After: 30 Sep 2027.
Before: Recruiting. After: Active not recruiting.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Change from baseline in the average number of heavy drinking days per week, with a heavy drinking day defined as 5 or more drinks in the day for men and 4 or more drinks in the day for women, using the TLFB method. After: Measure: Change from baseline in the average number of heavy drinking days per week.
Before: Estimated. After: Actual.
Before: May 2026. After: 30 Jul 2026.
Before: Active not recruiting. After: Completed.
NCT05989711 · Altimmune, Inc.
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis Measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis). After: Measure: Proportion of subjects achieving NASH resolution (NAFLD activity score [NAS], ballooning = 0; lobular inflammation = 0, 1) with at least a 2-point reduction in NAS without worsening of fibrosis Measure: Proportion of subjects achieving at least 1 stage improvement in liver fibrosis without worsening of NASH (defined as no change in the NAS, ie, the sum score for ballooning, inflammation, and steatosis) Measure: Incidence of Treatment Emergent Adverse Events.
Before: 29 Apr 2025. After: 25 Nov 2025.
NCT05989711 · Altimmune, Inc.
Before: Estimated. After: Actual.
Before: 190 participants (planned). After: 212 participants (actual).
Before: Active not recruiting. After: Completed.
NCT05989711 · Altimmune, Inc.
Before: 28 Feb 2025. After: 29 Apr 2025.